Unpacking A Potential 45% Upside In Biotech
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is capturing the attention of investors seeking opportunities in the dynamic biotechnology sector. With a robust pipeline of therapies targeting central nervous system (CNS) disorders, Axsome is well-positioned at the forefront of innovation in healthcare. As the company continues to expand its portfolio, recent stock analyses suggest a compelling potential for upside, making it an intriguing consideration for investors.
**Market Overview and Price Insights**
Axsome, with a market cap of $6.07 billion, is a prominent player in the biotechnology industry, focusing on the development of novel CNS disorder therapies. Currently trading at $121.71, Axsome’s stock has shown resilience within a…
